Navigation Links
Research suggests molecular 'switch' may play role in tumor suppression
Date:1/13/2013

llular distribution, this work will spur further research into unanticipated roles for this important molecule in healthy and diseased cells."

In endocytosis, trimeric clathrin molecules bind together to form molecular packages that allow other substances to enter cells. Several years ago, researchers in Japan published evidence that clathrin can also serve as an activator of the protein p53, a known tumor suppressor.

For the activation to take place, clathrin and p53 must both be present in the cell's nucleus. The catch is that clathrin molecules cannot penetrate the nucleus in their usual, three-legged form. To enter, the three-legged clathrin molecule must be altered or "de-trimerized."

Using X-ray crystallography, Ybe and his team discovered a "topology switch" in the clathrin molecule. They showed they could break the switch by mutating one key amino acid that is part of the switch. The result: Clathrin was "detrimerized"; three-legged molecules were broken into one-legged ones.

Experimenting with both cancer and non-cancer cells, the researchers found the three-legged clathrin only in the cytoplasm of the cells, not the nucleus. But with the "switch" broken, clathrin formed monomers and was also present in the nucleus, where it could potentially activate tumor suppression.

Ybe said the results point to the need for additional research to better understand the structure and function of clathrin and the role it plays in cellular processes, including those involved in cancer. With the clathrin "switch" identified, researchers can attempt to better understand how it can be activated, with the goal of developing new therapies for suppressing the growth of tumors. Ybe has a patent pending on the idea to use the mutated form of clathrin to stimulate the natural anti-cancer activities of human cells.

The finding developed from Ybe's research on the role of clathrin in Huntington's disease, a genetic disorder that c
'/>"/>

Contact: Steve Hinnefeld
slhinnef@iu.edu
812-856-3488
Indiana University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Canada In Vitro Diagnostics Market Analysis and Forecasts to 2017 in New Research Report at RnRMarketResearch.com
2. ZijaExtreme.com Researches Vitamin D Deficiency & Using a More Natural Approach
3. Spectacles Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research
4. Game-based economics research explains why we roll the dice on flu shots
5. Experts aim to redefine healthcare and research ethics
6. Heart Muscle Cells Regenerate in Kids, Research Shows
7. Research Reveals Which Learning Methods Get an A
8. Researchers use iPSCs to define optimal treatment for managing life-threatening arrhythmias
9. Dental Implants Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research
10. UT Arlington receives Grand Challenges Explorations grant for research in global health
11. Book co-authored by USF Nursing Dean named 2012 Nursing Research Book of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 05, 2015 The recent influx of ... promises is alarming, with more and more internet ads ... actual prescription, making it easy for more people to ... their money and endanger their health. The company urges ... prescription online diet pills: , 1.    Where are the products ...
(Date:3/5/2015)... 05, 2015 T.E.N., a technology ... honored finalists and winners Thursday evening, March 4, ... Awards Gala at the Westin Buckhead in Atlanta, ... for EarthLink, was selected as the Information Security ... ISE® Southeast Region. Pete is an industry veteran ...
(Date:3/5/2015)... Atlanta, Georgia (PRWEB) March 05, 2015 ... Atlanta’s top fertility practice, is holding an informational ... how to proactively plan for future families with egg ... Restaurant, Phipps Plaza, 3500 Peachtree Rd, Atlanta, GA, Time: ... Cost: Free, but RSVP required. Register here ! ...
(Date:3/5/2015)... What makes a legend? In the case of renowned Dallas ... exceptional courtroom performance, championing big causes and underdogs alike with ... service, the Dallas Bar Association has named Schmidt a Legend ... a luncheon on Tuesday, April 7, 2015 at 12 noon ... for this year are Bob Vial, Deborah Hankinson and Dick ...
(Date:3/5/2015)... Aliso Viejo, California (PRWEB) March 05, 2015 ... Pro X plugins have announced a new transition ... allows users to create split screen transitions with ease ... of Pixel Film Studios. “TranSlice Wipe is a time ... Wipe from Pixel Film Studios brings back split screen ...
Breaking Medicine News(10 mins):Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 2Health News:Diet Doc Announces Four Simple Questions that Dieters Must Ask Prior to Purchasing Online Diet Pills 3Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 2Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 3Health News:Pete Chronis of EarthLink and Jabil Claim Top Awards at ISE® Southeast 4Health News:Egg Freezing Seminar Allows Women to Pause the Biological Clock for Age, Social or Medical Reasons 2Health News:Egg Freezing Seminar Allows Women to Pause the Biological Clock for Age, Social or Medical Reasons 3Health News:C.L. Mike Schmidt Named "Legend In Trial Law" by Dallas Bar Association 2Health News:Pixel Film Studios Released TranSlice Wipe Exclusively for Final Cut Pro X Editors 2
... and Complex-Event Processing (CEP) Technologies Unified in Rx ... First Choice Professionals, LLC., today announced a partnership ... ), to provide healthcare organizations with advanced technology ... renowned healthcare integration group will combine talents with ...
... of Medicine created the Health ABC Heart Failure Model ... the elderly. Now that model has been strengthened ... data from an earlier cardiovascular study. , The results ... to identify high-risk individuals for whom interventions can be ...
... 30 Patients undergoing cancer treatment reported that using ... pain and itching associated with the sometimes-severe skin rashes ... of Health Sciences , the study substantiated the findings ... recognizing Regenecare for its pain-relieving and wound-healing benefits. Manufactured ...
... deliver clearer images, more accurate diagnoses and cost-effective ... Delivering on its promise to offer a portfolio ... high performance analog products to meet the needs ... (NYSE: TXN ) today announced the ...
... Pa., March 30 Genaera Corporation (Nasdaq: ... plan to conserve existing cash resources in order to ... trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B ... type 2 diabetes and obesity, and explore strategic alternatives. ...
... employer group health plans at a rate not seen in more ... insurance enrollments. Affordable medical insurance for small business is being called ... Federation of Independent Business and (NFIB) and America,s Health Insurance Plans ... ...
Cached Medicine News:Health News:First Choice Professionals and TIBCO Announce Strategic Partnership to Advance Healthcare Integration 2Health News:Heart failure risk model validated 2Health News:Patients Say MPM Medical's Regenecare Gel Significantly Reduced the Itching and Pain of Skin Rashes Triggered by Anti-Cancer Drugs 2Health News:Patients Say MPM Medical's Regenecare Gel Significantly Reduced the Itching and Pain of Skin Rashes Triggered by Anti-Cancer Drugs 3Health News:Medical imaging developers can speed time to market, improve performance, and lower development costs with TI's new embedded processor software toolkit 2Health News:Medical imaging developers can speed time to market, improve performance, and lower development costs with TI's new embedded processor software toolkit 3Health News:Medical imaging developers can speed time to market, improve performance, and lower development costs with TI's new embedded processor software toolkit 4Health News:Genaera Corporation Implements Cash Conservation Plan 2Health News:BestHealthcareRates.com Reports Highest Cancellation Rate of Employee Benefit Plans in More Than Two Decades 2Health News:BestHealthcareRates.com Reports Highest Cancellation Rate of Employee Benefit Plans in More Than Two Decades 3Health News:BestHealthcareRates.com Reports Highest Cancellation Rate of Employee Benefit Plans in More Than Two Decades 4
(Date:3/4/2015)... März 2015 Unfors RaySafe, ... Bereich diagnostische Röntgenstrahlung, stellte heute auf ... European Congress of Radiology (ECR) in ... einen neuen Strahlungsüberwachungssensor vor. ... Der RaySafe X2-Überwachungssensor stellt ...
(Date:3/4/2015)... 4, 2015  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... of the Phase II proof of concept clinical ... as a monotherapy in the treatment of chronic ... highly significant and clinically meaningful improvement from baseline ... measured on a 100mm unit Visual Analog Scale ...
(Date:3/4/2015)... Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the ... China, today announced its financial results for the fourth ... Quarter 2014 Financial Highlights , Total sales ... or 36.8% excluding the impact of foreign currency exchange ... the same quarter of 2013. , Gross profit ...
Breaking Medicine Technology:Unfors RaySafe, ein Unternehmen von Fluke Biomedical, stellt auf European Congress of Radiology neuen Überwachungssensor vor 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, stellt auf European Congress of Radiology neuen Überwachungssensor vor 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22
... SPRING, Md., Oct. 14 The Food and ... ,chelation, products—which claim to treat everything from autism ... metals. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... On Thursday, the agency warned eight companies ...
... The U.S. Health and ... (ASPE) has selected Thomson Reuters to develop a ... perform comparative effectiveness studies without the need for ... ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090507/NY12658LOGO ) ...
Cached Medicine Technology:Federal Government Selects Thomson Reuters to Build Tool That Streamlines Comparative Effectiveness Research 2
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
... new AquaGuide Ureteral Access Sheath, you can ... access sheath - plus an entirely new ... sheath is designed with a proprietary dual ... second working channel for a variety of ...
Used retrograde to dilate the ureter and establish a conduit for a flexible ureteroscope. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: